Study details
Enrolling now
Imaging Immune Activation in HIV by PET-MR
CellSight Technologies, Inc.
NCT IDNCT03684655ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
30
Study length
about 7.1 years
Ages
18+
Locations
1 site in CA
About this study
This trial is testing a treatment called [18F]F-AraG to see where it goes in the body when you have HIV. Participants will receive one injection of this drug and then undergo imaging scans using PET-MR technology. The goal is to understand how the drug distributes within the body, particularly in individuals with HIV.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)
PhasePhase 2
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low14%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Body systems
Immune, Infectious